Beyond First-Generation ICIs: Module 2 of OncoDaily Academy’s Six-Part Programme on Immune Checkpoint Inhibitors
FDA Grants Accelerated Approval to the First EGFR/MET-Targeted Therapy for HNSCC - The Babak Lab
Erika Hamilton: Plain Language Summary of HER2CLIMB-05 Trial in HER2+ mBC
Split-Course Lung SBRT: Novel Inhale–Exhale Technique May Reduce Rib and Chest Wall Radiation Exposure
Fabrice Barlesi: RAISE’s €100M Fund to Strengthen Medical Research at Gustave Roussy
PD-L1: One Biomarker, Three Different Scores
Premenopausal Breast Cancer: New Review Challenges One-Size-Fits-All Adjuvant Treatment Strategies
Manish Kohli: Beyond Genomics - A New Frontier in Prostate Cancer Liquid Biopsy Research
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
